UM 5050

UM 5050 is an investigational small-molecule prodrug platform originating from license agreements between Nemus Bioscience (now Skye Bioscience) and the University of Mississippi, described only as “UM 5050 pro-drug” in corporate filings without public disclosure of its precise active moiety, molecular target, or intended therapeutic indication. Available information indicates that it was conceived as part of a cannabinoid-related drug development portfolio but no peer‑reviewed or regulatory documents describing its pharmacology, clinical development, or disease focus have been made publicly accessible. As a result, its mechanism of action, specific target biology, and development stage remain undisclosed in the public domain.